Allopurinol adherence among patients with gout: An Italian general practice database study

International Journal of Clinical Practice

Volumn 69, Issue 7, 2015, Pages 757-765

  Mantarro, S ^a   Capogrosso Sansone, A ^a   Tuccori, M ^b   Blandizzi, C ^a,b   Montagnani, S ^a   Convertino, I ^b   Antonioli, L ^a   Fornai, M ^a   Cricelli, I ^c   Pecchioli, S ^c   Cricelli, C ^d   Lapi, F ^c  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c Health Search   (Italy)

^d Italian College of General Practitioners   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; URIC ACID; ANTIGOUT AGENT;

ADULT; AGED; ARTICLE; DATA BASE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; FEMALE; GENERAL PRACTICE; GOUT; HUMAN; HYPERURICEMIA; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTPATIENT; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; URIC ACID BLOOD LEVEL; ADOLESCENT; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; FACTUAL DATABASE; FOLLOW UP; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; STANDARDS; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENERAL PRACTICE; GOUT; GOUT SUPPRESSANTS; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; TIME FACTORS; URIC ACID; YOUNG ADULT;

EID: 84933278570     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12604     Document Type: Article

References (46)

1. Richette P, Bardin T,. Gout. Lancet 2010; 375: 318-28.
2. Neogi T,. Clinical practice. Gout. N Engl J Med 2011; 364: 443-52.
3. Campion EW, Glynn RJ, DeLabry LO,. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421-6.
4. Zhu Y, Pandya BJ, Choi HK,. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63: 3136-41.
5. Annemans L, Spaepen E, Gaskin M, et al., Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008; 67: 960-6.
6. Winnard D, Wright C, Taylor WJ, et al., National prevalence of gout derived from administrative health data in Aotearoa New Zealand. Rheumatology 2012; 51: 901-9.
7. Chuang SY, Lee SC, Hsieh YT, Pan WH,. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008. Asia Pac J Clin Nutr 2011; 20: 301-8.
8. Trifirò G, Morabito P, Cavagna L, et al., Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis 2013; 72: 694-700.
9. Miao Z, Li C, Chen Y, et al., Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol 2008; 35: 1859-64.
10. Vitart V, Rudan I, Hayward C, et al., SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437-42.
11. Guan M, Zhang J, Chen Y, Liu W, Kong N, Zou H,. High-resolution melting analysis for the rapid detection of an intronic single nucleotide polymorphism in SLC22A12 in male patients with primary gout in China. Scand J Rheumatol 2009; 20: 1-6.
12. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G,. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277-81.
13. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G,. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093-103.
14. Choi HK, Curhan G,. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008; 336: 309-12.
15. Khanna D, Fitzgerald JD, Khanna PP, et al.,; American College of Rheumatology Guidelines for Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64: 1431-46.
16. Khanna D, Khanna PP, Fitzgerald JD, et al.,; American College of Rheumatology Guidelines for Management of Gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1447-61.
17. Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA). Nota 91. 2/11/2010. http://www.agenziafarmaco.gov.it/it/content/nota-91 (accessed 27/03/2014).
18. Zhang W, Doherty M, Bardin T, et al., EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-24.
19. Coloma PM, Schuemie MJ, Trifirò G, et al., Drug-induced acute myocardial infarction: identifying 'prime suspects' from electronic healthcare records-based surveillance system. PLoS ONE 2013; 8: e72148.
20. Coloma PM, Valkhoff VE, Mazzaglia G, et al., Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries. BMJ Open 2013; 3: e002862.
21. Sterrantino C, Trifirò G, Lapi F, et al., Burden of community-acquired pneumonia in Italian general practice. Eur Respir J 2013; 42: 1739-42.
22. Lapi F, Simonetti M, Michieli R, et al., Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care. Bone 2012; 50: 85-90.
23. Filippi A, Vanuzzo D, Bignamini AA, Sessa E, Brignoli O, Mazzaglia G,. Computerized general practice databases provide quick and cost-effective information on the prevalence of angina pectoris. Ital Heart J 2005; 6: 49-51.
24. Mazzaglia G, Ambrosioni E, Alacqua M, et al., Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120: 1598-605.
25. Cricelli C, Mazzaglia G, Samani F, et al., Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med 2003; 25: 254-7.
26. Lawrenson R, Williams T, Farmer R,. Clinical information for research; the use of general practice databases. J Public Health Med 1999; 21: 299-304.
27. World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2014. http://www.whocc.no/atc-ddd-index/ (accessed 27/03/2014).
28. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC,. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009; 25: 2303-10.
29. Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodríguez LA,. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford) 2011; 50: 973-81.
30. Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR,. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin 2009; 25: 1711-9.
31. Harrold LR, Andrade SE, Briesacher BA, et al., Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009; 11: R46.
32. Sarawate CA, Brewer KK, Yang W, et al., Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006; 81: 925-34.
33. Riedel AA, Nelson M, Joseph-Ridge N, Wallace K, MacDonald P, Becker M,. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2004; 31: 1575-81.
34. Solomon DH, Avorn J, Levin R, Brookhart MA,. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis 2008; 67: 609-13.
35. Zandman-Goddard G, Amital H, Shamrayevsky N, Raz R, Shalev V, Chodick G,. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel. Rheumatology (Oxford) 2013; 52: 1126-31.
36. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG,. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64: 267-72.
37. Stamp LK,. Safety profile of anti-gout agents: an update. Curr Opin Rheumatol 2014; 26: 162-8.
38. Ryu HJ, Song R, Kim HW, et al., Clinical risk factors for adverse events in allopurinol users. J Clin Pharmacol 2013; 53: 211-6.
39. de Klerk E, van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden S,. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003; 30: 44-54.
40. Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y,. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006; 33: 104-9.
41. Chung Y, Stocker SL, Graham GG, Day RO,. Optimizing therapy with allopurinol: factors limiting hypouricemic efficacy. Am J Med Sci 2008; 335: 219-26.
42. Aarnio EJ, Martikainen JA, Helin-Salmivaara A, et al., Register-based predictors of adherence among new statin users in Finland. J Clin Lipidol 2014; 8: 117-25.
43. Baggarly SA, Kemp RJ, Wang X, Magoun AD,. Factors associated with medication adherence and persistence of treatment for hypertension in a Medicaid population. Res Social Adm Pharm 2014; 10: e99-e112.
44. Bailey JE, Hajjar M, Shoib B, Tang J, Ray MM, Wan JY,. Risk factors associated with antihypertensive medication nonadherence in a statewide medicaid population. Am J Med Sci 2014; 348: 410-5.
45. Rodriguez F, Cannon CP, Steg PG, et al., Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. Clin Cardiol 2013; 36: 721-7.
46. Warren JR, Falster MO, Fox D, Jorm L,. Factors influencing adherence in long-term use of statins. Pharmacoepidemiol Drug Saf 2013; 22: 1298-307.